https://doi.org/10.55788/755bf764
Dr Daniel Ignatiuk (Cincinnati Children’s Hospital, OH, USA) presented a retrospective study analysing OSA risk factors documented in a 10-year cohort of paediatric patients with PH at the Cincinnati Children’s Hospital, between January 2010 and August 2020 [1]. Identified were 403 patients aged 0–21 years who underwent diagnostic polysomnogram (PSG), including 89 patients with a documented diagnosis of PH (median age 3.6 years; range 9 days to 17.6 years). These 89 patients were sub-classified based on their PH group: group 1 (n=25; 28.1%), group 3 (n=31; 34.8%), and group 1/3 for patients meeting both group 1 and 3 criteria (n=33; 37.1%). Group 2 consisted of only 2 patients and was excluded from the analysis due to the low number.
Diagnosed sleep disorders included OSA (n=79; 88.8%), central sleep apnoea (n=11; 12.4%), hypoventilation (n=6; 6.7%), non-apnoeic hypoxaemia (n=28; 31.5%), and periodic limb movement disorder (n=5, 5.6%). OSA risk was increased with a diagnosis of trisomy 21 (RR 1.24; 95% CI 1.09–1.42; P<0.05).
However, OSA risk was decreased in group 1 compared with group 1/3 PH (RR 0.84; 95% CI 0.71–0.99; P<0.05) or group 3 PH (RR 0.81; 95% CI 0.68–0.96; P<0.05), and no difference in OSA risk between group 1 and group 3 PH was observed.
The take-home message for this study was that OSA was diagnosed in a majority of paediatric patients, most notably in patients with trisomy 21 or PH classification meeting both group 1 and 3 criteria. “Our research supports routine screening for OSA in this population, especially,” concluded Dr Ignatiuk.
- Ignatiuk D, et al. Risk for Obstructive Sleep Apnea in Pediatric Patients with Pulmonary Hypertension. Session A68, ATS International Conference 2022, San Francisco, CA, USA, 13–18 May.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« No screening evidence for COPD Next Article
POISE-3: Tranexamic acid for non-cardiac surgery »
« No screening evidence for COPD Next Article
POISE-3: Tranexamic acid for non-cardiac surgery »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil “futile” in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Three’s a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com